DaVita Inc. 2002 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: DaVita Inc.
Reporting Period: Fiscal year ended December 31, 2002
Business Overview: DaVita is the second-largest provider of dialysis services in the United States for patients with end-stage renal disease (ESRD). As of December 31, 2002, the company operated 515 outpatient dialysis centers in 33 states and the District of Columbia, serving approximately 45,000 patients. It also provides acute inpatient dialysis services in approximately 270 hospitals. The company completed the divestiture of its non-continental U.S. operations in 2002 (specifically Puerto Rico in June 2002), focusing entirely on the continental U.S. market.
Key Financial Metrics
| Metric | 2002 | 2001 | Change |
|---|---|---|---|
| Net Operating Revenues | $1,854.6 million | $1,650.8 million | +12.4% |
| Operating Income | $391.3 million | $318.0 million | +23.0% |
| Net Income | $157.3 million | $137.3 million | +14.6% |
| Diluted EPS | $1.96 | $1.52 | +29.0% |
| Operating Cash Flow | $342.0 million | $264.8 million | +29.2% |
| Long-Term Debt | $1,311.3 million | $811.2 million | +61.6% |
| Working Capital | $251.9 million | $176.0 million | +43.1% |
Revenue Composition: Medicare accounted for 51% of dialysis revenues, Medicaid 5%, and private payors/HMOs 44%. Approximately 25% of net operating revenues are derived from the administration of EPO (erythropoietin) and other pharmaceuticals.
Material Changes vs. Prior Period
- Recapitalization and Debt Restructuring: In 2002, DaVita executed a major recapitalization plan. It retired $225 million of Senior Subordinated Notes and secured a new $1.115 billion senior credit facility. This resulted in a $29.4 million extraordinary loss (net of tax) due to the write-off of deferred financing costs and debt redemption premiums. Consequently, long-term debt increased significantly from $811 million to $1.31 billion.
- Stock Repurchases: The company repurchased 27.3 million shares of common stock for $642 million during 2002, including a $402 million tender offer. This reduced the share count and increased earnings per share.
- Goodwill Accounting Change: Effective January 1, 2002, the company adopted SFAS No. 142, ceasing the amortization of goodwill. This eliminated approximately $42 million in amortization expense compared to 2001, contributing to higher operating income.
- Laboratory Revenue Recovery: Following a favorable administrative law judge ruling in June 2002 regarding its Florida laboratory, the company resumed recognizing Medicare lab revenue. It recognized approximately $59 million in prior-period lab revenue and $11 million in current-period lab revenue in the second half of 2002, reversing a policy of non-accrual used in 2001.
Guidance, Outlook, and Risks
2003 Guidance: Management projects 2003 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) to be in the range of $380 million to $400 million.
Management Commentary: Operating results for 2002 were in line with projections. The company expects non-acquired treatment growth to remain in the 3.0% to 5.0% range. Continued investments in new information technology systems are expected to continue through 2003.
Key Risks and Contingencies:
- Government Investigations: The company is cooperating with a U.S. Attorney's Office inquiry and an OIG subpoena regarding historical billing practices, financial relationships with physicians, and pharmaceutical services. The outcome is uncertain and could result in substantial penalties.
- Laboratory Disputes: The Florida laboratory remains under review by a third-party carrier for six periods. While the first two periods were ruled in DaVita's favor, hearings for the remaining four periods are scheduled for 2003. A Minnesota laboratory is also under post-payment review.
- Reimbursement Rates: Approximately 51% of revenue comes from Medicare. There is significant risk regarding potential reductions in reimbursement rates, particularly for EPO and other drugs, or the bundling of these services into the composite dialysis rate.
- Regulatory Compliance: The company faces risks related to anti-kickback statutes and Stark laws regarding financial relationships with referring physicians and medical directors.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new $1.115 billion credit facility covenants, given the increased leverage.
- Laboratory Resolution: Monitor the outcome of the carrier hearings for the Florida laboratory's third and fourth review periods scheduled for Q2 2003.
- Government Inquiry Status: Track developments in the U.S. Attorney's Office and OIG investigations regarding billing and physician relationships.
- EPO Reimbursement: Assess potential impacts of CMS drug pricing changes or bundling proposals on the ~25% of revenue derived from EPO administration.
- IT System Rollout: Evaluate the impact of the new information technology systems on billing efficiency and potential short-term disruptions.